343 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Oxford Asset Management LLP

Oxford Asset Management LLP bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, Holdings Channel.com reports. The firm bought 343 shares of the biopharmaceutical company’s stock, valued at approximately $244,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC increased its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of analyst reports. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price target for the company. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Finally, TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $945.32.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $602.64 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The firm has a 50-day moving average of $637.38 and a two-hundred day moving average of $721.91. The firm has a market capitalization of $65.88 billion, a PE ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.